Skip to main content

Table 4 LFTs results and clinical evaluation at three months

From: Clinical, radiological and functional outcomes in patients with SARS-CoV-2 pneumonia: a prospective observational study

Parameters Normal range Overall (39) CT improving at 3 month (31) CT not improving at 3 month (8) P value
FEV 1 (l) (mean ± SD)   2.9 ± 0.7 3.0 ± 0.7 2.6 ± 0.7 0.045
FEV 1 (% ± SD)   93.4 ± 16.1 95.1 ± 14.8 89.6 ± 15.6 0.52
FVC (l) (mean ± SD)   3.7 ± 0.9 3.8 ± 0.9 3.5 ± 1.1 0.97
Obstruction (n and %)   3 (7.7) 1 (3.2) 2 (25) 0.10
Restriction (n and %)   3 (7.7) 2 (6.5) 1 (12.5) 0.50
Abnormal DLCO (n and %)   22 (56.4) 18 (58.1) 4 (50) 0.71
DLCO (%, mean ± SD) > 75 71.3 ± 15.5 70.5 ± 11.5 74.1 ± 26.5 0.62
LFTs abnormalities (n and %)   25 (64.1) 20 (64.6) 5 (62.5) 1
6MWT (m, mean ± SD)   539.3 ± 102.8 545.8 ± 96.6 514 ± 134.1 0.33
SpO2 at rest at 3 month (%, mean ± SD) 95–100 95.6 ± 1.6 95.7 ± 1.7 95 ± 1.2 0.10
SpO2 effort at 3 month (%, mean ± SD) 95–100 91.3 ± 3.5 91.2 ± 3.9 91.4 ± 1.9 0.43
mMRC score (≥ 2) at 3 month (n and %)   6 (15.4) 4 (12.9) 2 (25) 0.58